Irina Vierasu, Hugo Levillain, Martina Pezzullo, Jennifer Dhont, Hugues Azema, Hugo Couvert, Clémentine Marin, Nicola Trotta, Simon Lacroix, Ana-Maria Bucalau, Gontran Verset, Anne Demols, Marianne Paesmans, Desislava Germanova, Valerio Lucidi, Eric Trépo, Thierry Gustot, Christophe Moreno, Jean-Luc Van Laethem, Patrick Flamen
{"title":"Limited Added Prognostic Value of Choline PET/CT in Treatment-Naïve Hepatocellular Carcinoma.","authors":"Irina Vierasu, Hugo Levillain, Martina Pezzullo, Jennifer Dhont, Hugues Azema, Hugo Couvert, Clémentine Marin, Nicola Trotta, Simon Lacroix, Ana-Maria Bucalau, Gontran Verset, Anne Demols, Marianne Paesmans, Desislava Germanova, Valerio Lucidi, Eric Trépo, Thierry Gustot, Christophe Moreno, Jean-Luc Van Laethem, Patrick Flamen","doi":"10.1055/s-0046-1824460","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This retrospective study aimed to assess whether choline PET/CT provides additional independent prognostic value compared with magnetic resonance imaging (MRI) and [ <sup>18</sup> F]FDG PET/CT in treatment-naïve patients with hepatocellular carcinoma (HCC). A total of 78 treatment-naïve patients with predominantly single-lesion and early-stage HCC who underwent MRI, [ <sup>18</sup> F]FDG PET/CT, and choline PET/CT were retrospectively included.</p><p><strong>Results: </strong>Higher than median MRI-, choline and [ <sup>18</sup> F]FDG PET/CT-derived tumor volumes were associated with poorer overall survival (OS) in univariate analyses. An MRI-derived tumor volume > 17.81 mL was associated with worse OS ( <i>p</i> = 0.005; hazard ratio [HR], 3.15; 95% confidence interval [CI], 1.41-7.03), as were choline PET/CT tumor volume > 8.4 mL ( <i>p</i> = 0.04; HR, 2.27; 95% CI, 1.03-5.01) and [ <sup>18</sup> F]FDG positivity ( <i>p</i> = 0.02; HR, 2.74; 95% CI, 1.11-6.81). After multivariate analysis with correction for multiple testing, only MRI-derived tumor volume remained an independent predictor of OS. Although associated with OS in univariate analyses, choline PET-derived metrics did not retain statistical significance after adjustment, suggesting limited incremental prognostic information beyond MRI-derived tumor burden. Liver transplantation and hepatectomy were associated with superior survival compared with locoregional therapies ( <i>p</i> = 0.006). No significant correlations were observed between imaging parameters and α-fetoprotein (AFP) levels or ALBI score (all <i>p</i> > 0.05). Interaction analyses did not detect any significant modification of the prognostic effect of choline PET imaging biomarkers by AFP levels, ALBI score, or Child-Pugh class. Treatment modality emerged as the strongest prognostic factor in the penalized model using least absolute shrinkage and selection operator regularization, while choline PET-derived parameters did not show independent prognostic value.</p><p><strong>Conclusion: </strong>Choline PET/CT did not demonstrate additional independent prognostic value beyond MRI or [ <sup>18</sup> F]FDG PET/CT in this cohort of treatment-naïve patients with predominantly early-stage and single-lesion HCC.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 3","pages":"208-218"},"PeriodicalIF":1.0000,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13612106/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0046-1824460","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Background: This retrospective study aimed to assess whether choline PET/CT provides additional independent prognostic value compared with magnetic resonance imaging (MRI) and [ 18 F]FDG PET/CT in treatment-naïve patients with hepatocellular carcinoma (HCC). A total of 78 treatment-naïve patients with predominantly single-lesion and early-stage HCC who underwent MRI, [ 18 F]FDG PET/CT, and choline PET/CT were retrospectively included.
Results: Higher than median MRI-, choline and [ 18 F]FDG PET/CT-derived tumor volumes were associated with poorer overall survival (OS) in univariate analyses. An MRI-derived tumor volume > 17.81 mL was associated with worse OS ( p = 0.005; hazard ratio [HR], 3.15; 95% confidence interval [CI], 1.41-7.03), as were choline PET/CT tumor volume > 8.4 mL ( p = 0.04; HR, 2.27; 95% CI, 1.03-5.01) and [ 18 F]FDG positivity ( p = 0.02; HR, 2.74; 95% CI, 1.11-6.81). After multivariate analysis with correction for multiple testing, only MRI-derived tumor volume remained an independent predictor of OS. Although associated with OS in univariate analyses, choline PET-derived metrics did not retain statistical significance after adjustment, suggesting limited incremental prognostic information beyond MRI-derived tumor burden. Liver transplantation and hepatectomy were associated with superior survival compared with locoregional therapies ( p = 0.006). No significant correlations were observed between imaging parameters and α-fetoprotein (AFP) levels or ALBI score (all p > 0.05). Interaction analyses did not detect any significant modification of the prognostic effect of choline PET imaging biomarkers by AFP levels, ALBI score, or Child-Pugh class. Treatment modality emerged as the strongest prognostic factor in the penalized model using least absolute shrinkage and selection operator regularization, while choline PET-derived parameters did not show independent prognostic value.
Conclusion: Choline PET/CT did not demonstrate additional independent prognostic value beyond MRI or [ 18 F]FDG PET/CT in this cohort of treatment-naïve patients with predominantly early-stage and single-lesion HCC.